Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for paternal testing
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators
Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology
Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting
Podium presentation showcases the clinical application of Precise™ MRD
Craig-Hallum Initiates Myriad Genetics Stock with a Buy Rating
Craig-Hallum Initiates Myriad Genetics Stock with a Buy Rating
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference
Opening plenary session features latest fetal fraction amplification research
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
Study Demonstrates RiskScore as a More Accurate Predictor of Breast Cancer Risk, Doubling Accuracy Compared to the Tyrer-Cuzick Model
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
Prolaris, MyRisk, and Precise Tumor Testing Validated Across Cancer Stages, Elevating Company’s Comprehensive Patient-Centric Solutions
